Blueberries Medical Corp.

As of June 30, 2026, Blueberries Medical Corp. carries a market capitalization of 3.22M, placing it among publicly traded companies globally. Its enterprise value stands at 3.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Blueberries Medical Corp.'s next confirmed earnings release is scheduled for November 30, 2026.

As of June 30, 2026, Blueberries Medical Corp. has 495.09M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 18.76, and the price-to-book ratio stands at 182.07.

These figures are as of June 30, 2026. The EV/Sales ratio of 20.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.46M versus a market cap of 3.22M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Blueberries Medical Corp. maintains a current ratio of 0.44, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Blueberries Medical Corp. posted a negative return on equity (ROE) of -220.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -106.46, reflecting losses generated across the asset base. Inventory turnover of 0.86 indicates how many times Blueberries Medical Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Blueberries Medical Corp.'s stock has declined approximately 53.85% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended June 30, 2026, Blueberries Medical Corp. generated 171,584.60 in revenue and converted that into -659,365.41 in net income, yielding earnings per share of 0.00. EBITDA reached -613,957.69, while operating income came in at -466,904.99.

As of June 30, 2026, Blueberries Medical Corp. holds 9,108.80 in cash and equivalents against 249,131.25 in total debt, resulting in a net debt position of 234,914.51. Total book value stands at 17,674.87, with working capital of -220,739.09 providing operational flexibility.

Blueberries Medical Corp. produced -359,981.86 in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Blueberries Medical Corp. posted a gross margin of 55.17, reflecting its pricing power and cost economics. The operating margin of -272.11 and net profit margin of -384.28 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.19: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.57, meaning Blueberries Medical Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Blueberries Medical Corp.'s most recent stock split took place on July 4, 2018 with a 10:1 split ratio.

As of June 30, 2026, Blueberries Medical Corp. has an Altman Z-Score of -56.97, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.